Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

d for the full year 2007.

General and administrative expenses in the fourth quarter of 2007 decreased to $1.8 million from $3.0 million in the year ago period resulting mainly from cost controls and less outsourced services. General and administrative expenses for the full year 2007 decreased to $6.1 million from $7.7 million for the full year 2006. This decrease was principally a result of legal and consulting expenses capitalized upon the completion of the IPO in 2007 compared to costs related to the unsuccessful IPO attempt in 2006 that were expensed.

On December 31, 2007, ImaRx had $12.9 million in cash, cash equivalents and investments, excluding $0.4 million in restricted cash, compared to $4.3 million in cash, cash equivalents and investments on December 31, 2006. The increase in the cash balance was primarily related to the $9.0 million sale of Abbokinase, net of discounts and fees, to two primary wholesale distributors and the $12.4 million in net proceeds received from the common stock offering in connection with the Company's July 2007 IPO. Assuming the tentative agreement with Abbott regarding the remaining balance of the $15.0 million note is executed and a strategic financing alternative for SonoLysis is achieved, the Company believes it will have sufficient cash resources for at least the next 12 months.

Additionally, in connection with the filing of its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2008, Ernst & Young LLP, the Company's independent registered public accounting firm, noted that the Company has recurring losses, which has resulted in a significant accumulated deficit at December 31, 2007. In addition, the Company has a significant note payable balance due on March 31, 2008. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern.

Conference Call and Webcast Information

Management will host a conferen
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... --  BioTE Medical , a leading provider of ... today announced the addition of Dr. Neal ... is joining the BioTE Medical Advisory Board as ... was residency trained in Family Medicine and Emergency ... emergency physician still practicing at a large metropolitan ...
(Date:7/22/2014)... The DNA Spectrum Ancestry Map provides ... history, migration, and culture. , Throughout his childhood ... stories stemming from Europe. His father passionately referred to ... 8mm home movies painted an elaborate picture of an ... ordered a test from DNA Spectrum to expand upon ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 /PRNewswire/ ... filiale di BGI, la maggiore organizzazione di genomica del ... servizio di sequenziamento dell,intero esoma umano con base la ... Complete Genomics, molto apprezzata nel settore per essere ... il 99.999% di precisione e una rilevazione altamente sensibile ...
(Date:7/22/2014)... 22, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today announced that it will report second ... U.S. financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., ... conference call at 11 a.m. EDT, July 25, 2014. ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
... BEDMINSTER, N.J., Nov. 8, 2010 Omthera ... company, today announced the initiation of a ... evaluate the bioavailability of Epanova™, Omthera,s lead ... triglycerides, in comparison to Lovaza®, the leading ...
... (Nasdaq: TPCG ) today announced that it has commenced ... of its common stock at a purchase price of not less ... purchase shares having an aggregate purchase price of no more than ... stockholders may tender all or a portion of their shares (1) ...
... at the Kavli Institute of NanoScience, has been awarded ... his research into improved microscopic technologies. The technologies enable ... semiconductor nanowires, all the way down to atomic level. ... are made visible in this way can be measured ...
Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 2TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 4ERC advanced grant for Professor Zandbergen's 'nanolaboratory' 2
(Date:7/22/2014)... Arlington computer science and engineering professor with an expertise ... National Science Foundation grant worth more than $600,000 to ... fruit fly., Heng Huang, an associate professor, will lead ... UT Arlington Computer Science and Engineering department. Scientists are ... a large number of genes involved in fruit fly ...
(Date:7/22/2014)... the average steak, but it seems to help wood ... winter cold. , "Alaska wood frogs spend more time ... your freezer and the frog comes back to life ... said Don Larson, University of Alaska Fairbanks graduate student ... freeze tolerance in Alaska wood frogs is more extreme ...
(Date:7/22/2014)... the USC Schaeffer Center for Health Policy and ... drugs with increased incarceration rates for schizophrenic individuals. ... whether cutbacks in mental health actually save money, ... Some health plans require an extra approval step ... patients. This step called prior authorization ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... Sept. 26 2007 -- Consuming large amounts of caffeine ... painkillers in the United States, could potentially cause liver ... the Oct. 15 print issue of ACS Chemical Research ... occur not only from drinking caffeinated beverages while taking ...
... the magnetic reference direction, have recently been found in ... 2004). Furthermore, studies investigating what parts of a migratory ... magnetic compass showed that the cryptochrome-containing neurons in the ... al., PNAS, 2005; Liedvogel et al., EJN, 2007) are ...
... 25, 2007) Your body goes to a lot of ... brains neural pathways are impaired through injury, age or illness, ... to perform the constant yet delicate balancing act required for ... robots that can balance like humans, researchers at Georgia Tech ...
Cached Biology News:Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 2Simulation reveals how body repairs balance after damage 2Simulation reveals how body repairs balance after damage 3